Cargando…

COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies

• The pandemic COVID-19 requires alternative methods and thinking to keep healthcare professionals and patients safe. • In COVID-19 hot spots, oral therapies may be viable alternatives to intravenous therapies for treatment of ovarian cancer. • Minimizing patient visits to hospitals and cancer clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monk, Bradley J., Coleman, Robert L., Moore, Kathleen N., Herzog, Thomas J., Secord, Angeles Alvarez, Matulonis, Ursula A., Slomovitz, Brian M., Guntupalli, Saketh R., O'Malley, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188656/ https://www.ncbi.nlm.nih.gov/pubmed/32370991 http://dx.doi.org/10.1016/j.ygyno.2020.04.703

Ejemplares similares

Clinical trials, adaptability and the COVID-19 pandemic
por: Eskander, Ramez N., et al.
Publicado: (2020)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

The role of immune checkpoint inhibition in the treatment of ovarian cancer
por: Gaillard, Stéphanie L., et al.
Publicado: (2016)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
por: Pitiyarachchi, Omali, et al.
Publicado: (2022)

Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer
por: Davidson, Brittany A, et al.
Publicado: (2014)

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
por: Gershenson, David M, et al.
Publicado: (2022)

Quinary debulking for epithelial ovarian cancer
por: Edwards, James M., et al.
Publicado: (2012)

Endometrial cancer: molecular classification and future treatments
por: Corr, Bradley, et al.
Publicado: (2022)

Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report
por: Watson, Catherine H., et al.
Publicado: (2020)

PARP Inhibitors in Ovarian Cancer: A Review
por: O’Malley, David M., et al.
Publicado: (2023)

Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?
por: Herzog, Thomas J., et al.
Publicado: (2017)

Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer
por: Kim, Youngchul, et al.
Publicado: (2014)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

Low-grade serous ovarian cancer: expert consensus report on the state of the science
por: Grisham, Rachel N, et al.
Publicado: (2023)

A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
por: Porragas-Paseiro, Hector S., et al.
Publicado: (2023)

Cotyledonoid dissecting leiomyoma with adipocytic differentiation: A case report()
por: Blake, Erin A., et al.
Publicado: (2014)

Utilizing preoperative arterial embolization to minimize blood loss at time of vulvar sarcoma resection: A case report
por: Schulte, Vera, et al.
Publicado: (2022)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field
por: Coleman, Robert L, et al.
Publicado: (2014)

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
por: Monk, Bradley J., et al.
Publicado: (2020)

Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
por: Mahdi, Haider, et al.
Publicado: (2023)

90 Years of progesterone: Ninety years of progesterone: the ‘other’ ovarian hormone
por: Ali, Simak, et al.
Publicado: (2020)

Preparedness of Ob/Gyn residents for fellowship training in gynecologic oncology
por: Doo, David W., et al.
Publicado: (2015)

Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention
por: George, Sophia H. L., et al.
Publicado: (2016)

Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin
por: Abghari, Pamella F., et al.
Publicado: (2017)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy
por: Dotson, Sarah, et al.
Publicado: (2018)

The perceptions of gynecologic oncology fellows on readiness for subspecialty training following OB/GYNRESIDENCY
por: Urban, Renata R., et al.
Publicado: (2019)

Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis
por: Stuver, Robert, et al.
Publicado: (2018)

Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program
por: Cetin, Karynsa, et al.
Publicado: (2011)

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
por: Martin, Lainie P., et al.
Publicado: (2017)

Ovarian Cancer: Current Treatment and Patient Management
por: Monk, Bradley J., et al.
Publicado: (2016)

Metastatic adenocarcinoma after laparoscopic supracervical hysterectomy with morcellation: A case report()
por: Turner, Taylor, et al.
Publicado: (2013)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
por: Przybytkowski, Ewa, et al.
Publicado: (2020)

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks
por: Yu, Kun-Hsing, et al.
Publicado: (2020)

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
por: Monk, Bradley J, et al.
Publicado: (2021)

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2018)

A latitudinal cline in the Chinook salmon (Oncorhynchus tshawytscha) Clock gene: evidence for selection on PolyQ length variants
por: O'Malley, Kathleen G, et al.
Publicado: (2008)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7618cilb0f74nfq6j6t75io5mt